Cigna earnings beat by $0.04, revenue topped estimates
DENTSPLY SIRONA Inc. (NASDAQ:XRAY), a leader in dental equipment and supplies with a market capitalization of $3.2 billion and annual revenue of $3.7 billion, disclosed the outcomes of its annual stockholders’ meeting held on May 21, 2025. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculation, despite facing profitability challenges in the past twelve months. The meeting’s key agenda items included the election of directors, ratification of the company’s independent auditor, advisory approval of executive compensation, and an amendment to the incentive plan.
All eleven director nominees were elected to serve until the next annual meeting, with votes for each ranging from 165,989,940 to 174,918,214. Deloitte and Touche LLP were ratified as the company’s independent registered public accountants for 2025, receiving an overwhelming majority of votes in favor at 187,599,963. The non-binding advisory vote on the company’s executive compensation for 2024 passed with 170,911,500 votes for, 4,944,479 against, and 907,227 abstentions. This comes as InvestingPro data shows management’s commitment to shareholder returns through aggressive share buybacks and maintaining dividend payments for 32 consecutive years, despite current market challenges.
Additionally, the stockholders approved Amendment No. 1 to the Company’s 2024 Omnibus Incentive Plan, which increases the number of shares of Common Stock issuable under the plan by 11,260,000 shares. The amendment received 165,989,940 votes for, 10,631,325 against, and 141,941 abstentions.
Broker non-votes were reported for each of the items requiring a stockholder vote, indicating shares present at the meeting but not voted on specific proposals. The number of broker non-votes for each proposal was 11,338,487.
The results of the meeting are based on a press release statement filed with the SEC. The filing ensures transparency and provides investors with insights into the governance and future direction of the company. Looking ahead, 13 analysts have revised their earnings estimates upward, with InvestingPro data revealing multiple additional positive indicators available in the comprehensive Pro Research Report, which provides deep-dive analysis of DENTSPLY SIRONA among 1,400+ top US stocks.
In other recent news, Dentsply Sirona Inc. reported its first-quarter 2025 earnings, surpassing analyst expectations with an adjusted earnings per share (EPS) of $0.43, compared to the forecasted $0.3036. The company achieved revenue of $879 million, slightly above the anticipated $859.26 million. Despite a 7.7% year-over-year decline in revenue, the company managed to expand its adjusted EBITDA margins by 220 basis points. Analysts from Evercore ISI and Leerink Partners have been closely monitoring the company’s performance, particularly in light of ongoing economic uncertainties and tariff impacts. Dentsply Sirona has been focusing on innovation, with enhancements in its DS Core ecosystem and PrimeScan technology, maintaining its competitive edge in the dental market. The company anticipates a 2-4% decline in organic sales for the remainder of 2025, with adjusted EPS expected to range between $1.80 and $2.00. The ongoing search for a new Chief Financial Officer is in its late stages, with the company expecting to make an announcement soon.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.